pwrm getting some activity

wow those numbers are great diffidently gotta keep my eye on PWRM

No change in price

last trade .0138 doing a volume of 29.5k ask is .012x5000
bid is .013x5000

Stem Cell companies could break out!
I would watch PWRM
You can still buy PWRM for less than .02 a share at .0138

Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:
Breast Cancer Chemotherapeutic Drug Resistance
Alzheimer's Disease Leukemia
ALS (Lou Gehrig's Disease) Gastrointestinal Disease
Parkinson's Disease Metabolic Syndrome

These discovered and patent-pending biomarkers solve critical challenges facing pharmaceutical and diagnostic companies and are currently being used to design tests to diagnose diseases and discover targets for new drugs to treat the diseases. [/CENTER]

Power3 Medical Products, Inc.
3400 Research Forest Drive
Suite B2-3
Woodlands, TX 77381

http://www.power3medical.com

* Phone: (281) 466-1600
* E-mail: c5healthcare@yahoo.com

__________________
“The only interesting answers are those which destroy the questions.”

Moderators, I did a symbol search and it showed Invalid Prefix. You can delete this if you like as I saw another Message on it

Sorry

I guess I used the search function wrong

__________________
“The only interesting answers are those which destroy the questions.”

Friday July 31, 2009

**************************************************************
Power3 Medical Products, Inc. Files for Patent on “Diagnosis of Early Stage Parkinson’s Disease”

Las Vegas CRWENewswire -Power3 Medical Products, Inc. (OTCBB:PWRM), (Power3 Medical Products -- Tracking the footprints of disease), today announced that the Company has filed a patent for “Diagnosis of Early Stage Parkinson’s Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.”

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinson’s disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinson’s, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test. This work was done in conjunction with Transgenomic, Inc. license/collaboration agreement. The patent provides coverage of biomarkers and the computation/statistical methods used to discriminate the disease vs. the normal controls.

“Power3 Medical is continuing the portfolio of it intellectual property in Neurodegenerative diagnosis”, We recently filed a patent on the ability of Power3;s Nuro-Pro-PD test, using a series of abnormal blood serum biomarkers, to distinguish the early onset of Parkinson’s disease ,” stated Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3. “This patent is a break through declaration of new discoveries in this field”

“We are continually increasing our value with the exemplary patent filings for our biomarker discovery and validation. This is especially timely for the Nuro-Pro PD since we are striving to commercialize with our Collaborator, Transgenomic, Inc., via. CLIA testing in the late fall of 2009.” Commented Ms. Helen R. Park, CEO of Power3. “This adds value to Power3 and to our Licensee/Collaborator, Transgenomic, Inc.”

About Power3 Medical Products, Inc.

Power3 Medical Products, Inc. (OTCBB:PWRM - News) (Power3 Medical Products -- Tracking the footprints of disease), is a leading Bio Medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio.

Forward Looking Statement

This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.

Contact:

Power3 Medical Products, Inc., The Woodlands, TX
CEO
Helen R. Park, M.S., 281-466-1600
Fax: 281-466-1481
hpark@power3medical.com

Power3 Medical Products -- Tracking the footprints of disease

Power3 Medical Products, Inc. Files for Patent on “Diagnosis of Early Stage Parkinson?s Disease” (DrStockPick News Report!) | CROWN EQUITY HOLDINGS, INC.

__________________
“The only interesting answers are those which destroy the questions.”

Power3 Medical Products, Inc. (OTCBB:PWRM) has filed a patent for “Diagnosis of Early Stage Parkinson’s Disease: Abnormal: Blood Serum Concentrations of a Select Group of Protein Biomarkers.”

Power3 Medical Products, Inc. filed a provisional patent on the diagnosis of early stage Parkinson’s disease: abnormal blood serum concentrations of a select group of protein biomarkers. This not only announces to the industry the progress of the Nuro-Pro-PD test for Parkinson’s, in validation, utility, but that the importance of the Power3 protein biomarkers are statistically valid for use as a diagnostic test. This work was done in conjunction with Transgenomic, Inc. license/collaboration agreement. The patent provides coverage of biomarkers and the computation/statistical methods used to discriminate the disease vs. the normal controls.

“Power3 Medical is continuing the portfolio of it intellectual property in Neurodegenerative diagnosis”, We recently filed a patent on the ability of Power3;s Nuro-Pro-PD test, using a series of abnormal blood serum biomarkers, to distinguish the early onset of Parkinson’s disease ,” stated Dr. Ira L. Goldknopf, President and Chief Scientific Officer of Power3. “This patent is a break through declaration of new discoveries in this field”

“We are continually increasing our value with the exemplary patent filings for our biomarker discovery and validation. This is especially timely for the Nuro-Pro PD since we are striving to commercialize with our Collaborator, Transgenomic, Inc., via. CLIA testing in the late fall of 2009.” Commented Ms. Helen R. Park, CEO of Power3. “This adds value to Power3 and to our Licensee/Collaborator, Transgenomic, Inc.”

PWRM have moved 645,330shares...as is the same with many companies right now PWRM had to have a little trouble befor they could have a little joy...the difference is PWRM imo will be trading like hot cakes soon enough...so do a lil research.look for it and you will see what i see to...happy hunting.